A Review of the Role of Insulin-like Growth Factor 2 in Malignancy and its Potential as a Modifier of Radiation Sensitivity

Clinical Oncology

Volumn 20, Issue 5, 2008, Pages 345-352

  Jacobs, C I ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Clonogenic survival; IGF 1R; IGF1; IGF2; irradiation

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 4 AMINO 5 (3 BENZYLOXYPHENYL) 7 [3 (1 PYRROLIDINYLMETHYL)CYCLOBUTYL] 7H PYRROLO[2,3 D]PYRIMIDINE; ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; COMPLEMENTARY RNA; EVEROLIMUS; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY A12; OLIGONUCLEOTIDE; PROTEIN KINASE B INHIBITOR; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ARTICLE; CANCER GENE THERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; HUMAN; LIGAND BINDING; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; INSULIN-LIKE GROWTH FACTOR II; LIGANDS; MICE; NEOPLASMS; RADIATION TOLERANCE; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; SOMATOMEDINS;

EID: 43049157995     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2008.02.004     Document Type: Article

References (66)

1. LeRoith D., and Roberts Jr. C.T. The insulin-like growth factor system and cancer. Cancer Lett 195 2 (2003) 127-137
2. Renehan A.G., Zwahlen M., Minder C., et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363 9418 (2004) 1346-1353
3. Christofori G., Naik P., and Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 369 6479 (1994) 414-418
4. Hahn H., Wojnowski L., Specht K., et al. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem 275 37 (2000) 28341-28344
5. Samani A.A., Yakar S., LeRoith D., et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28 1 (2007) 20-47
6. Warshamana-Greene G.S., Litz J., Buchdunger E., et al. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy. Clin Cancer Res 11 4 (2005) 1563-1571
7. Foulstone E., Prince S., Zaccheo O., et al. Insulin-like growth factor ligands, receptors, and binding proteins in cancer. J Pathol 205 2 (2005) 145-153
8. Garcia-Echeverria C., Pearson M.A., Marti A., et al. In vivo antitumor activity of NVP-AEW541 - a novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 5 3 (2004) 231-239
9. Scheid M.P., and Woodgett J.R. Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett 546 1 (2003) 108-112
10. Testa J.R., and Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci U S A 98 20 (2001) 10983-10985
11. Sun M., Wang G., Paciga J.E., et al. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 159 2 (2001) 431-437
12. Liaw D., Marsh D.J., Li J., et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16 1 (1997) 64-67
13. Cui H., Cruz-Correa M., Giardiello F.M., et al. Loss of IGF2 imprinting: a potential marker of colorectal cancer risk. Science 299 5613 (2003) 1753-1755
14. Liu J.P., Baker J., Perkins A.S., et al. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igf1r). Cell 75 1 (1993) 59-72
15. Baker J., Liu J.P., Robertson E.J., et al. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 75 1 (1993) 73-82
16. Feinberg A.P. The epigenetics of cancer etiology. Semin Cancer Biol 14 6 (2004) 427-432
17. DeChiara T.M., Efstratiadis A., and Robertson E.J. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature 345 6270 (1990) 78-80
18. Leighton P.A., Ingram R.S., Eggenschwiler J., et al. Disruption of imprinting caused by deletion of the H19 gene region in mice. Nature 375 6526 (1995) 34-39
19. Lee J.E., Pintar J., and Efstratiadis A. Pattern of the insulin-like growth factor II gene expression during early mouse embryogenesis. Development 110 1 (1990) 151-159
20. Cui H., Horon I.L., Ohlsson R., et al. Loss of imprinting in normal tissue of colorectal cancer patients with microsatellite instability. Nat Med 4 11 (1998) 1276-1280
21. Duguay S.J., Jin Y., Stein J., et al. Post-translational processing of the insulin-like growth factor-2 precursor. Analysis of O-glycosylation and endoproteolysis. J Biol Chem 273 29 (1998) 18443-18451
22. Scheid M.P., and Woodgett J.R. PKB/AKT: functional insights from genetic models. Nat Rev Mol Cell Biol 2 10 (2001) 760-768
23. Sasaoka T., Rose D.W., Jhun B.H., et al. Evidence for a functional role of Shc proteins in mitogenic signaling induced by insulin, insulin-like growth factor-1, and epidermal growth factor. J Biol Chem 269 18 (1994) 13689-13694
24. McKenna W.G., Muschel R.J., Gupta A.K., et al. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 22 37 (2003) 5866-5875
25. Peruzzi F., Prisco M., Dews M., et al. Multiple signaling pathways of the insulin-like growth factor 1 receptor in protection from apoptosis. Mol Cell Biol 19 10 (1999) 7203-7215
26. Datta S.R., Dudek H., Tao X., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 2 (1997) 231-241
27. Pap M., and Cooper G.M. Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell survival pathway. J Biol Chem 273 32 (1998) 19929-19932
28. Mayo L.D., and Donner D.B. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 98 20 (2001) 11598-11603
29. She Q.B., Solit D.B., Ye Q., et al. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8 4 (2005) 287-297
30. Kandel E.S., Skeen J., Majewski N., et al. Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol 22 22 (2002) 7831-7841
31. Lawlor M.A., and Alessi D.R. PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?. J Cell Sci 114 pt 16 (2001) 2903-2910
32. Tran H., Brunet A., Grenier J.M., et al. DNA repair pathway stimulated by the forkhead transcription factor FOXO3a through the Gadd45 protein. Science 296 5567 (2002) 530-534
33. Carraway H., and Hidalgo M. New targets for therapy in breast cancer: mammalian target of rapamycin (mTOR) antagonists. Breast Cancer Res 6 5 (2004) 219-224
34. Huang S., and Houghton P.J. Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 3 4 (2003) 371-377
35. Jenkins P.J., Frajese V., Jones A.M., et al. Insulin-like growth factor I and the development of colorectal neoplasia in acromegaly. J Clin Endocrinol Metab 85 9 (2000) 3218-3221
36. Ward A. Beck-Wiedemann syndrome and Wilms' tumour. Mol Hum Reprod 3 2 (1997) 157-168
37. De Souza A.T., Hankins G.R., Washington M.K., et al. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/insulin-like growth factor II receptor locus in human hepatocellular tumors. Oncogene 10 9 (1995) 1725-1729
38. Hankins G.R., De Souza A.T., Bentley R.C., et al. M6P/IGF2 receptor: a candidate breast tumor suppressor gene. Oncogene 12 9 (1996) 2003-2009
39. Daughaday W.H., and Kapadia M. Significance of abnormal serum binding of insulin-like growth factor II in the development of hypoglycemia in patients with non-islet-cell tumors. Proc Natl Acad Sci U S A 86 17 (1989) 6778-6782
40. Davda R., and Seddon B.M. Mechanisms and management of non-islet cell tumour hypoglycaemia in gastrointestinal stromal tumour: case report and a review of published studies. Clin Oncol (R Coll Radiol) 19 4 (2007) 265-268
41. Pazzaglia S., Mancuso M., Atkinson M.J., et al. High incidence of medulloblastoma following X-ray-irradiation of newborn Ptc1 heterozygous mice. Oncogene 21 49 (2002) 7580-7584
42. Su L.K., Kinzler K.W., Vogelstein B., et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256 5057 (1992) 668-670
43. Hassan A.B., and Howell J.A. Insulin-like growth factor II supply modifies growth of intestinal adenoma in Apc(Min/+) mice. Cancer Res 60 4 (2000) 1070-1076
44. Sakatani T., Kaneda A., Iacobuzio-Donahue C.A., et al. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 307 5717 (2005) 1976-1978
45. Harper J., Burns J.L., Foulstone E.J., et al. Soluble IGF2 receptor rescues Apc(Min/+) intestinal adenoma progression induced by Igf2 loss of imprinting. Cancer Res 66 4 (2006) 1940-1948
46. Allen G.W., Saba C., Armstrong E.A., et al. Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res 67 3 (2007) 1155-1162
47. Wen B., Deutsch E., Marangoni E., et al. Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. Br J Cancer 85 12 (2001) 2017-2021
48. Turner B.C., Haffty B.G., Narayanan L., et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 57 15 (1997) 3079-3083
49. Macaulay V.M., Salisbury A.J., Bohula E.A., et al. Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase. Oncogene 20 30 (2001) 4029-4040
50. Trojan J., Cloix J.F., Ardourel M.Y., et al. Insulin-like growth factor type I biology and targeting in malignant gliomas. Neuroscience 145 3 (2007) 795-811
51. Brognard J., Clark A.S., Ni Y., et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 61 10 (2001) 3986-3997
52. Albert J.M., Kim K.W., Cao C., et al. Targeting the Akt/mammalian target of rapamycin pathway for radiosensitization of breast cancer. Mol Cancer Ther 5 5 (2006) 1183-1189
53. Yu D., Watanabe H., Shibuya H., et al. Redundancy of radioresistant signaling pathways originating from insulin-like growth factor I receptor. J Biol Chem 278 9 (2003) 6702-6709
54. Yu D., Shibuya H., and Miura M. Roles of the insulin-like growth factor I receptor C-terminus in cellular radioresistance. Biochem Biophys Res Commun 311 1 (2003) 174-178
55. Nakamura S., Watanabe H., Miura M., et al. Effect of the insulin-like growth factor I receptor on ionizing radiation-induced cell death in mouse embryo fibroblasts. Exp Cell Res 235 1 (1997) 287-294
56. LeRoith D., and Helman L. The new kid on the block(ade) of the IGF-1 receptor. Cancer Cell 5 3 (2004) 201-202
57. Min Y., Adachi Y., Yamamoto H., et al. Insulin-like growth factor I receptor blockade enhances chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer xenografts. Gut 54 5 (2005) 591-600
58. Zhang L., Kim M., Choi Y.H., et al. Diminished G1 checkpoint after gamma-irradiation and altered cell cycle regulation by insulin-like growth factor II overexpression. J Biol Chem 274 19 (1999) 13118-13126
59. Burns J.L., and Hassan A.B. Cell survival and proliferation are modified by insulin-like growth factor 2 between days 9 and 10 of mouse gestation. Development 128 19 (2001) 3819-3830
60. Yu T., MacPhail S.H., Banath J.P., et al. Endogenous expression of phosphorylated histone H2AX in tumors in relation to DNA double-strand breaks and genomic instability. DNA Repair (Amst) 5 8 (2006) 935-946
61. Hall E.J., and Wuu C.S. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 56 1 (2003) 83-88
62. Hartog H., Wesseling J., Boezen H.M., et al. The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 43 13 (2007) 1895-1904
63. Andrews D.W., Resnicoff M., Flanders A.E., et al. Results of a pilot study involving the use of an antisense oligodeoxynucleotide directed against the insulin-like growth factor type I receptor in malignant astrocytomas. J Clin Oncol 19 8 (2001) 2189-2200
64. Chan S., Scheulen M.E., Johnston S., et al. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer. J Clin Oncol 23 23 (2005) 5314-5322
65. Goudar R.K., Shi Q., Hjelmeland M.D., et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4 1 (2005) 101-112
66. Prince S.N., Foulstone E.J., Zaccheo O.J., et al. Functional evaluation of novel soluble insulin-like growth factor (IGF)-II-specific ligand traps based on modified domain 11 of the human IGF2 receptor. Mol Cancer Ther 6 2 (2007) 607-617